Cargando…
Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma
Parafollicular C-cell-derived medullary thyroid cancer (MTC) comprises 3% to 4% of all thyroid cancers. While cytotoxic treatments have been shown to have limited efficacy, targeted molecular therapies that inhibit rearranged during transfection (RET) and other tyrosine kinase receptors that are mai...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594951/ https://www.ncbi.nlm.nih.gov/pubmed/23509459 http://dx.doi.org/10.1155/2013/803171 |
_version_ | 1782262366933614592 |
---|---|
author | Giunti, Serena Antonelli, Alessandro Amorosi, Andrea Santarpia, Libero |
author_facet | Giunti, Serena Antonelli, Alessandro Amorosi, Andrea Santarpia, Libero |
author_sort | Giunti, Serena |
collection | PubMed |
description | Parafollicular C-cell-derived medullary thyroid cancer (MTC) comprises 3% to 4% of all thyroid cancers. While cytotoxic treatments have been shown to have limited efficacy, targeted molecular therapies that inhibit rearranged during transfection (RET) and other tyrosine kinase receptors that are mainly involved in angiogenesis have shown great promise in the treatment of metastatic or locally advanced MTC. Multi-tyrosine kinase inhibitors such as vandetanib, which is already approved for the treatment of progressive MTC, and cabozantinib have shown distinct advantages with regard to rates of disease response and control. However, these types of tyrosine kinase inhibitor compounds are able to concurrently block several types of targets, which limits the understanding of RET as a specific target. Moreover, important resistances to tyrosine kinase inhibitors can occur, which limit the long-term efficacy of these treatments. Deregulated cellular signaling pathways and genetic alterations in MTC, particularly the activation of the RAS/mammalian target of rapamycin (mTOR) cascades and RET crosstalk signaling, are now emerging as novel and potentially promising therapeutic treatments for aggressive MTC. |
format | Online Article Text |
id | pubmed-3594951 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-35949512013-03-18 Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma Giunti, Serena Antonelli, Alessandro Amorosi, Andrea Santarpia, Libero Int J Endocrinol Review Article Parafollicular C-cell-derived medullary thyroid cancer (MTC) comprises 3% to 4% of all thyroid cancers. While cytotoxic treatments have been shown to have limited efficacy, targeted molecular therapies that inhibit rearranged during transfection (RET) and other tyrosine kinase receptors that are mainly involved in angiogenesis have shown great promise in the treatment of metastatic or locally advanced MTC. Multi-tyrosine kinase inhibitors such as vandetanib, which is already approved for the treatment of progressive MTC, and cabozantinib have shown distinct advantages with regard to rates of disease response and control. However, these types of tyrosine kinase inhibitor compounds are able to concurrently block several types of targets, which limits the understanding of RET as a specific target. Moreover, important resistances to tyrosine kinase inhibitors can occur, which limit the long-term efficacy of these treatments. Deregulated cellular signaling pathways and genetic alterations in MTC, particularly the activation of the RAS/mammalian target of rapamycin (mTOR) cascades and RET crosstalk signaling, are now emerging as novel and potentially promising therapeutic treatments for aggressive MTC. Hindawi Publishing Corporation 2013 2013-02-21 /pmc/articles/PMC3594951/ /pubmed/23509459 http://dx.doi.org/10.1155/2013/803171 Text en Copyright © 2013 Serena Giunti et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Giunti, Serena Antonelli, Alessandro Amorosi, Andrea Santarpia, Libero Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma |
title | Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma |
title_full | Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma |
title_fullStr | Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma |
title_full_unstemmed | Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma |
title_short | Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma |
title_sort | cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594951/ https://www.ncbi.nlm.nih.gov/pubmed/23509459 http://dx.doi.org/10.1155/2013/803171 |
work_keys_str_mv | AT giuntiserena cellularsignalingpathwayalterationsandpotentialtargetedtherapiesformedullarythyroidcarcinoma AT antonellialessandro cellularsignalingpathwayalterationsandpotentialtargetedtherapiesformedullarythyroidcarcinoma AT amorosiandrea cellularsignalingpathwayalterationsandpotentialtargetedtherapiesformedullarythyroidcarcinoma AT santarpialibero cellularsignalingpathwayalterationsandpotentialtargetedtherapiesformedullarythyroidcarcinoma |